PT141 (10mg)

Description

What is PT-141 (Bremelanotide)?

PT‑141 (bremelanotide, brand name Vyleesi®, Palatin Technologies / AMAG) is a cyclic heptapeptide melanocortin‑receptor agonist derived from an N‑terminal fragment of Melanotan‑2. Unlike PDE5 inhibitors which act peripherally, bremelanotide acts centrally at MC4 receptors in hypothalamic circuits involved in sexual arousal. It is FDA‑approved (2019) as a subcutaneous on‑demand autoinjector for acquired, generalized HSDD in premenopausal women.

Mechanism of Action

• Preferential agonism at MC4R in hypothalamus; partial MC3R activity
• Centrally mediated sexual arousal response, independent of peripheral vascular mechanism of PDE5 inhibitors
• Effects on desire and arousal in both preclinical and clinical sexual‑behavior models
• Commercial dosing: 1.75 mg SC autoinjector, on‑demand, not more than once per 24 h and not more than 8 times per month

Compound Properties

• Molecular formula: C₅₀H₆₈N₁₄O₁₀
• Molecular weight: ~1025.18 g/mol
• CAS: 189691‑06‑3
• Sequence: Ac‑Nle‑cyclo[Asp‑His‑D‑Phe‑Arg‑Trp‑Lys]‑OH
• Form: Lyophilized powder
• Unit size: 10 mg / vial
• Source: Solid‑phase peptide synthesis; ≥98% purity by HPLC

Research‑Reference Dosing

Published research‑reference ranges from clinical trials:

• Kingsberg et al., Obstetrics & Gynecology (2019) — RECONNECT trial: bremelanotide 1.75 mg SC in HSDD (premenopausal women).
• Simon et al., Women’s Health (2019): safety profile in long‑term extension.
• Diamond et al., Journal of Sexual Medicine (2012): earlier ED studies (program discontinued in men for efficacy).

Research Findings

• Statistically significant improvement in sexual desire and reduced distress in RECONNECT (Kingsberg 2019)
• FDA approval 2019 for HSDD
• Erectile‑dysfunction program in men was discontinued due to insufficient efficacy

Known Side Effects Reported in Research/Trials

• Nausea (~40% at 1.75 mg; most common AE)
• Flushing, headache, injection‑site reaction
• Transient increase in systolic BP (~2–6 mmHg) for several hours; contraindicated in uncontrolled hypertension or cardiovascular disease per label
• Focal hyperpigmentation of face, gingiva, breasts (dose‑dependent, reversible after discontinuation)

Storage & Handling

• Lyophilized (unreconstituted) vials: store at −20°C long‑term; short‑term 2–8°C acceptable.
• After reconstitution with bacteriostatic or sterile water: store at 2–8°C; use within 14–28 days per standard peptide stability guidance.
• Protect from light, heat, and repeated freeze‑thaw cycles. Handle in a sterile laboratory environment.

Certificate of Analysis

A Certificate of Analysis (COA) confirming identity and purity by HPLC / MS is available upon request. Contact Lonestar Peptides for lot‑specific documentation.

Summaries reference peer‑reviewed preclinical and clinical literature available as of early 2025. Newer findings may not be reflected. Researchers should consult current literature and conduct their own due diligence. Lonestar Peptides makes no claim of therapeutic benefit.